{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T15:45:52Z","timestamp":1772293552327,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13365-024-01227-6","type":"journal-article","created":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T17:01:50Z","timestamp":1724000510000},"page":"441-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Progressive multifocal leukoencephalopathy in sarcoidosis successfully treated with pembrolizumab"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8743-4412","authenticated-orcid":false,"given":"Gizem","family":"\u00d6zt\u00fcrk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif \u0130rem","family":"Tekeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyda","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Peker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan","family":"Y\u00fccesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"issue":"15","key":"1227_CR2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR -Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80(15):1430\u20131438. https:\/\/doi.org\/10.1212\/WNL.0b013e31828c2fa1","journal-title":"Neurology"},{"key":"1227_CR15","doi-asserted-by":"publisher","first-page":"e01514","DOI":"10.1016\/j.idcr.2022.e01514","volume":"28","author":"T -Chatterjee","year":"2022","unstructured":"Chatterjee T, Roy M, Lin RC, Almoujahed MO, Ahmad S (2022) Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: a case report and literature review. IDCases 28:e01514. https:\/\/doi.org\/10.1016\/j.idcr.2022.e01514","journal-title":"IDCases"},{"issue":"17","key":"1227_CR13","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I -Cortese","year":"2019","unstructured":"Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A (2019) Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med 380(17):1597\u20131605. https:\/\/doi.org\/10.1056\/NEJMoa1815039","journal-title":"N Engl J Med"},{"issue":"5700","key":"1227_CR12","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1126\/science.1103492","volume":"306","author":"GF -Elphick","year":"2004","unstructured":"Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306(5700):1380\u20131383. https:\/\/doi.org\/10.1126\/science.1103492","journal-title":"Science"},{"issue":"6","key":"1227_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s13365-023-01180-w","volume":"29","author":"S -Fan","year":"2023","unstructured":"Fan S, Liu M, Bai L, Chen S, Hou B, Lin N, Yuan J, Mao C, Niu J, Ren H, Zhao Y, Zhang Z, Zhu Y, Peng B, Guan H (2023) Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy in China. J Neurovirol 29(6):692\u2013698. https:\/\/doi.org\/10.1007\/s13365-023-01180-w","journal-title":"J Neurovirol"},{"issue":"15","key":"1227_CR3","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1212\/WNL.0000000000000318","volume":"82","author":"Y -Jamilloux","year":"2014","unstructured":"Jamilloux Y, N\u00e9el A, Lecouffe-Desprets M, F\u00e8vre A, Kerever S, Guillon B, Bouvry D, Varron L, Redares C, Dominique S, Roux M, Chapelon-Abric C, Valeyre D, Ducray F, Bernard C, Broussolle C, Hamidou M, S\u00e8ve P (2014) Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology 82(15):1307\u20131313. https:\/\/doi.org\/10.1212\/WNL.0000000000000318","journal-title":"Neurology"},{"issue":"2","key":"1227_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ana.20933","volume":"60","author":"IJ -Koralnik","year":"2006","unstructured":"Koralnik IJ (2006) Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 60(2):162\u2013173. https:\/\/doi.org\/10.1002\/ana.20933","journal-title":"Ann Neurol"},{"issue":"6","key":"1227_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaneurol.2023.0841","volume":"80","author":"CRS -McEntire","year":"2023","unstructured":"McEntire CRS, Fletcher A, Toledano M, Epstein S, White E, Tan CS, Mao-Draayer Y, Banks SA, Aksamit AJ, Gelfand JM, Thakur KT, Anand P, Cortese I, Bhattacharyya S (2023) Characteristics of Progressive Multifocal Leukoencephalopathy Associated with Sarcoidosis without Therapeutic Immune suppression. JAMA Neurol 80(6):624\u2013633. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0841","journal-title":"JAMA Neurol"},{"issue":"5","key":"1227_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s004150170175","volume":"248","author":"DA -Nowak","year":"2001","unstructured":"Nowak DA, Widenka DC (2001) Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 248(5):363\u2013372. https:\/\/doi.org\/10.1007\/s004150170175","journal-title":"J Neurol"},{"issue":"7712","key":"1227_CR1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/s0140-6736(71)91777-6","volume":"1","author":"BL -Padgett","year":"1971","unstructured":"Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1(7712):1257\u20131260. https:\/\/doi.org\/10.1016\/s0140-6736(71)91777-6","journal-title":"Lancet"},{"issue":"6","key":"1227_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.crad.2010.03.001","volume":"65","author":"R -Shah","year":"2010","unstructured":"Shah R, Bag AK, Chapman PR, Cur\u00e9 JK (2010) Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 65(6):431\u2013439. https:\/\/doi.org\/10.1016\/j.crad.2010.03.001","journal-title":"Clin Radiol"},{"issue":"4","key":"1227_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS -Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9(4):425\u2013437. https:\/\/doi.org\/10.1016\/S1474-4422(10)70040-5","journal-title":"Lancet Neurol"},{"key":"1227_CR7","doi-asserted-by":"publisher","first-page":"578248","DOI":"10.1016\/j.jneuroim.2023.578248","volume":"385","author":"K -Varmpompiti","year":"2023","unstructured":"Varmpompiti K, Westwood AJ, Ben-Joseph A, Sibtain N, Ibrahim MAA, Stanton B, Zuckerman M, Hadden R, Ritter LM (2023) Progressive multifocal leukoencephalopathy secondary to idiopathic CD4 lymphocytopenia treated with pembrolizumab. J Neuroimmunol 385:578248. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578248","journal-title":"J Neuroimmunol"},{"key":"1227_CR4","doi-asserted-by":"publisher","first-page":"bcr0320114036","DOI":"10.1136\/bcr.03.2011.4036","volume":"2012","author":"J Zeitz","year":"2012","unstructured":"Hohlfeld SK, G\u00fcnthard HF, Zeitz J, Locher, Bachli E (2012) Progressive multi-focal leukoencephalopathy as a rare lethal complication in untreated sarcoidosis. BMJ case Rep 2012:bcr0320114036. https:\/\/doi.org\/10.1136\/bcr.03.2011.4036","journal-title":"BMJ case Rep"},{"key":"1227_CR14","doi-asserted-by":"publisher","unstructured":"Pasquier D RA (2019) Pembrolizumab as a treatment for PML? Waiting for Godot. Neurology(R) Neuroimmunol Neuroinflammation 6(6):e629. https:\/\/doi.org\/10.1212\/NXI.0000000000000629","DOI":"10.1212\/NXI.0000000000000629"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-024-01227-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-024-01227-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-024-01227-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T20:22:44Z","timestamp":1729974164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-024-01227-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s13365-024-01227-6","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}